2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|July 26, 2017
Corning and Gerresheimer Collaborate on Valor Glass
Author(s)Pharmaceutical Technology Editors
Corning and Gerresheimer have been working together to accelerate innovations for pharmaceutical glass packaging.
Advertisement
Valor Glass is a breakthrough glass container engineered for the storage and delivery of injectable drugs. Its strength, chemical durability, and damage resistance result in better protection for drug products. Valor Glass also enables increased throughput and higher levels of quality assurance for pharmaceutical companies.
Corning and Gerresheimer have been working together since 2015 to accelerate Corning innovations for the pharmaceutical glass packaging market.
“We are thrilled to be working with Corning on innovations to enhance quality across the industry. Valor Glass is a remarkable Type I glass with outstanding performance on every attribute,” said Uwe Röhrhoff, CEO of Gerresheimer AG, in a press release on July 24, 2017.
“Gerresheimer is a long-standing leader in the industry. They’ve been a terrific collaboration partner, and we’re excited to be working with them to bring Valor Glass to the pharmaceutical industry,” said Ron Verkleeren, vice-president and general manager, Corning Pharmaceutical Technologies, in the release.
Source:
Advertisement
Related to this article
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Tavapadon Sets Development Benchmark for Parkinson's
2
KRAS G12D Inhibitor's $2.13B Deal Tests Cross-Border Tech Transfer
3
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
4
PharmTech’s Weekly Roundup—September 25, 2026
5